Aug 2026· Cell Reports· Vol 45, pp. 117785 - 117785· 0 citations· 102 references
Medicine
TL;DR
Findings identify CARM1 as a regulator of GSC developmental programs and NGFR/NTRK-dependent survival and a role for CARM1-dependent NFIA methylation in NGFR repression in NGFR repression.
Abstract
SUMMARY Glioma stem-like cells (GSCs) exploit developmental signaling programs that contribute to glioblastoma heterogeneity and therapy resistance. Here, we define a role for the arginine methyltransferase coactivator-associated arginine methyltransferase 1 (CARM1) in regulating GSC lineage state and survival signaling. CARM1 depletion slows GSC growth, increases apoptosis, alters histone post-translational modifications, and shifts transcriptomic and proteomic profiles toward a radial glial-like state. Loss of CARM1 increases NGFR/NTRK signaling and sensitizes GSCs to NTRK and AKT inhibition. Mechanistically, NFIA is a CARM1 substrate, and mutation of NFIA arginine 389 increases NGFR expression, supporting a role for CARM1-dependent NFIA methylation in NGFR repression. In orthotopic xenografts, CARM1 depletion reduces tumor burden and prolongs survival. These findings identify CARM1 as a regulator of GSC developmental programs and NGFR/NTRK-dependent survival.
Results implicate TNIK in the mechanisms linking epithelial-mesenchymal plasticity with proliferation and evasion of senescence and provide insights into future strategies for the clinical deployment of TNIK inhibitors in LUSC and other TNIK-dependent malignancies.
Mohaddase Hamidi, Kenneth O. Omolo, Korrey W. Hart et al.· bioRxiv· 0 citations
Findings identify coordinated suppression of a FOXM1-associated MCPH program as part of the GBM radiation response, while suggesting that the radiosensitizing effects of pharmacological FOXM1inhibition extend beyond this transcriptional axis.
L. Van Eupen, E. Etlioglu, K. Tabury et al.· bioRxiv· 0 citations
ABSTRACT Glioblastoma multiforme (GBM), the most lethal type of primary brain tumor, exhibits profound metabolic plasticity driven by glioma stem cells (GSCs), which sustain therapeutic resistance and tumor recurrence. Here, we elucidate a novel epigenetic‐metabolic axis mediated by the histone acetyltransferase KAT7 t...
Ji-Long Liu, Yan-Fei Sun, Yue-Hua Zhu et al.· Advancement of science· 0 citations
The conceptual boundaries and operational criteria for identifying OnF in CRC are discussed, its regulatory mechanisms, plasticity-associated phenotypes, and translational relevance are examined, and the importance of distinguishing direct evidence of OnF from evidence of related plasticity mechanisms is emphasized.
Hao-Yu Wang, Song-Hao Liu, Ming-Xuan Zhang et al.· Frontiers in Oncology· 0 citations
Together, these data show that ZFP36L2 acts as an important molecular switch that couples stress sensing with phenotypic plasticity, which in turn drives cellular dedifferentiation essential for re-establishing the ISC state during wound healing and metastasis.
Qi Jiang, Manisha S. Raghavan, Aileen M. Rodriguez et al.· Nature· 0 citations
This review examines how BRN2 connects developmental neurogenesis to therapy-induced tumor reprogramming and integrates insights from neurodevelopment and direct lineage reprogramming to describe how BRN2 maintains stem-like and neuroendocrine transcriptional states.
